Yabao Pharmaceutical Group Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products include Chinese and Western medicine preparations, patches, active pharmaceutical ingredients and pharmaceutical packaging materials. The Company's products mainly involve pediatrics, adult medicines and health products. The Company sells its products under the brands of Yabao, Dinggui, Yabao Lishu and Yabao Weiyuan. The Company mainly operates its businesses in the domestic and overseas markets.

Employees

3,415

Sector

Pharmaceuticals

Calendar

10-28 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
28/10/26	CN¥7.150	+7.84%	81,058,474
27/10/26	CN¥6.630	-3.21%	16,672,700
26/10/26	CN¥6.850	-0.15%	14,786,300
23/10/26	CN¥6.860	+3.63%	27,599,800
22/10/26	CN¥6.620	-3.78%	30,056,650

End-of-day quote Shanghai S.E.

More quotes

End-of-day quote Shanghai S.E. 28/10/2026			5-day change	1st Jan Change
7.150 ^CNY	+7.84%		+3.92%	+10.17%

10-27	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2026	CI
10-08	Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on July 31, 2026.	CI

Market Cap	4.95B 742M 666M 616M 558M 1.04B 70.68B 1.05B 7.36B 2.93B 36.99B 2.78B 2.73B 117B	P/E 2024	18.1x	P/E 2025	14.2x
Enterprise Value	4.16B 624M 560M 518M 469M 876M 59.47B 887M 6.19B 2.47B 31.12B 2.34B 2.29B 98.8B	EV / Sales 2024	1.45x	EV / Sales 2025	1.65x
Free-Float	79.74%	Yield 2024	4.93%	Yield 2025	5.39%

10-27	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2026	CI
10-08	Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on July 31, 2026.	CI
08-01	Shanxi Yabao Pharmaceutical Logistics Distribution Co., Ltd. announced that it expects to receive CNY 50 million in funding from Yabao Pharmaceutical Group Co., Ltd	CI
08-01	Beijing Yabao Biopharmaceutical Co., Ltd. announced that it has received CNY 100 million in funding from Yabao Pharmaceutical Group Co., Ltd	CI
07-31	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-31	Yabao Pharmaceutical Group Co., Ltd announces an Equity Buyback for CNY 200 million worth of its shares.	CI
07-31	Yabao Pharmaceutical Group Co., Ltd authorizes a Buyback Plan.	CI
05-25	Yabao Pharmaceutical Subsidiary Secures Chinese Regulatory Approval for High Cholesterol Tablets	MT
04-24	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-24	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
12-22	Shanxi Tongxiang Times Technology Co., Ltd. completed the acquisition ofan additional 62% stake in Yabao Pharmaceutical Taiyuan Pharmaceutical Co., Ltd. from Yabao Pharmaceutical Group Co., Ltd.	CI
12-18	Yabao Pharma Gets Clinical Trial Nod for Pulmonary Arterial Hypertension Drug	MT
11-17	Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 17, 2025.	CI

30/06/16	Yabao Pharmaceutical : Pharmaceuticals and LFB Biomedicaments Enter Into Strategic Partnership to Deliver VIALEBEX® (LFB’s Human Albumin) in China	BU
20/04/16	Yabao Pharmaceutical : Pharmaceuticals and Salus Pharma Announce Strategic Partnership for Generic Drugs	BU
12/01/16	Yabao Pharmaceuticals : and Sciecure Pharma Announce Strategic Partnership to Co-develop, Manufacture and Commercialize Generics for U.S. and China	BU
20/10/15	Yabao Pharmaceuticals : Enters Second Innovative Collaboration With Eli Lilly and Company to Develop Diabetes Treatment	BU
15/09/15	Yabao Pharmaceuticals : and Primary Peptides Announce Exclusive China Partnership	BU

Yabao Pharmaceutical Group Co., Ltd Stock

Stocks

600351

CNE000001CM5

Pharmaceuticals

Valuation: Yabao Pharmaceutical Group Co., Ltd

Chart: Yabao Pharmaceutical Group Co., Ltd

Latest news: Yabao Pharmaceutical Group Co., Ltd

Press Releases: Yabao Pharmaceutical Group Co., Ltd

News in other languages: Yabao Pharmaceutical Group Co., Ltd

Quotes and Performance

Price Extremes

Managers and Directors: Yabao Pharmaceutical Group Co., Ltd

Generic Pharmaceuticals

Financials

Company Profile

Quotes

1 day	+7.84%
1 week	+3.92%
Current month	+4.84%
1 month	+4.69%
3 months	+10.17%
6 months	+3.47%
Current year	+10.17%

1 week	6.52	7.29
1 month	6.52	7.29
Current year	5.6	7.45
1 year	5.6	7.45
3 years	4.94	9
5 years	4.94	11.9
10 years	4.5	11.9

Manager	Title	Age	Since
Wei Ren CEO	Chief Executive Officer	42	23/04/2019
Zhe Feng Zuo DFI	Director of Finance/CFO	54	17/05/2017
Peng Bo Ren PRN	Corporate Officer/Principal	53	11/03/2007

Director	Title	Age	Since
Wu Xian Ren CHM	Chairman	66	26/05/2005
Peng Bo Ren BRD	Director/Board Member	53	15/05/2014
Wei Ren BRD	Director/Board Member	42	23/04/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
YABAO PHARMACEUTICAL GROUP CO., LTD	+7.84%	+3.92%	+7.04%	-16.86%	688M
ELI LILLY AND COMPANY	+0.50%	+1.38%	+57.09%	+129.96%	1,143B
JOHNSON & JOHNSON	+0.86%	+5.14%	+45.00%	+86.15%	647B
ABBVIE INC.	-0.14%	+0.42%	+25.69%	+105.85%	506B
ROCHE HOLDING AG	-0.05%	+1.73%	+52.74%	+67.74%	384B
MERCK & CO., INC.	-0.63%	-5.97%	+61.93%	+37.06%	350B
NOVARTIS AG	+0.34%	+1.84%	+30.70%	+54.27%	293B
ASTRAZENECA PLC	-0.45%	+1.19%	+2.89%	+26.08%	265B
AMGEN INC.	+0.87%	+3.08%	+54.69%	+72.74%	242B
GILEAD SCIENCES, INC.	+0.08%	+3.67%	+35.05%	+107.78%	197B
Average	+0.92%	+2.11%	+37.28%	+67.08%	402.82B
Weighted average by Cap.	+0.26%	+1.55%	+44.49%	+89.00%

	2024	2025
Net sales	2.69B 403M 361M 334M 303M 565M 38.37B 572M 4B 1.59B 20.08B 1.51B 1.48B 63.74B	2.24B 336M 301M 279M 252M 472M 32B 477M 3.33B 1.33B 16.74B 1.26B 1.23B 53.16B
Net income	243M 36.4M 32.66M 30.19M 27.35M 51.09M 3.47B 51.71M 361M 144M 1.81B 137M 134M 5.76B	320M 48M 43.06M 39.81M 36.06M 67.37M 4.57B 68.18M 476M 190M 2.39B 180M 176M 7.59B
Net Debt	-483M -72.43M -64.98M -60.08M -54.41M -102M -6.9B -103M -718M -286M -3.61B -272M -266M -11.46B	-784M -118M -106M -97.59M -88.38M -165M -11.2B -167M -1.17B -465M -5.86B -441M -432M -18.61B